Rockwell Medical, Inc. (DE) Common Stock
RMTIRockwell Medical, Inc. (RMTI) is a pharmaceutical company specializing in the development and commercialization of products for the treatment of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Founded in 1994, the company focuses on iron-based therapies and other specialty dialysis products, aiming to improve patient outcomes and provide innovative treatment options in the nephrology space.
Company News
Rockwell Medical reported Q2 2025 earnings with a 37.8% revenue decline due to losing its largest customer, but signed four new multi-year supply agreements and maintained tight cost controls.
DaVita's stock has gained 47.3% year-to-date, outperforming the industry and the S&P 500. The rally is attributed to the company's strong dialysis and lab services, solid Q2 2024 performance, and expansion through acquisitions.
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In the latest trading session, Rockwell Medical (RMTI) closed at $1.65, marking a +1.85% move from the previous day.
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 125% and 0.01%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
